

Pantodac

Pantoprazole USP

Composition:

Pantodac 20: Each enteric coated tablet contains Pantoprazole Sodium Sesquihydrate USP equivalent to Pantoprazole 20 mg.

Pantodac 40: Each enteric coated tablet contains Pantoprazole Sodium Sesquihydrate USP equivalent to Pantoprazole 40 mg.

Description:

Pantodac enteric coated tablet is a preparation of Pantoprazole which is a proton pump inhibitor indicated for the treatment of acid-peptic diseases. Like other proton pump inhibitors **Pantodac** causes long-lasting inhibition of acid secretion by inactivating the parietal cell H⁺-K⁺ ATPase.

Indications:

Pantoprazole is indicated where suppression of acid secretion is of therapeutic benefit, it therefore has a role similar to that of H₂ receptor antagonists and omeprazole.

Pantodac is indicated for the following purposes :

Duodenal ulcer, benign gastric ulcer, esophagitis/ulceration, Zollinger-Ellison Syndrome, resistant ulcers, eradication of *Helicobacter pylori* in the treatment of peptic ulcer (in combination with antibiotics) and in the treatment of ulcers induced by Non-Steroidal Antiinflammatory Drugs (NSAIDs).

Dosage and Administration:

The usual recommended adult oral dose is 40 mg once daily, preferably in the morning with or without food.

Duodenal ulcer: 40 mg daily in the morning for two weeks, continued for further two weeks if not fully healed.

Gastric ulcer: 40 mg daily for 4 weeks, continued for further 4 weeks if not fully healed.

Gastro-esophageal reflux disease: 40 mg daily in the morning for four weeks, continued for further four weeks if not fully healed 20 mg daily may be continued (long-term management). Increased to 40 mg daily if symptoms return.

Duodenal ulcer associated with *Helicobacter pylori*: 40 mg twice daily associated with appropriate antibiotic regimen.

Ulcer induced by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Pantoprazole 40 mg daily has been used to prevent the formation of gastroduodenal lesions in patients receiving continuous treatment with NSAIDs.

Gastro-intestinal bleeding from stress or acid peptic diseases: The usual adult oral dose is 40 mg once daily, preferably in the morning with or without food, if required dose may be increased.

Contraindications:

In patients with known hypersensitivity to Pantoprazole Sodium Sesquihydrate or any excipient of the formulation.

Side effects:

Side effects of the proton pump inhibitors include gastro-intestinal disturbances (including diarrhoea, nausea and vomiting, constipation, flatulence, abdominal pain), headache, hypersensitivity reactions (including rash, urticaria, angioedema, bronchospasm), pruritus, dizziness, peripheral oedema, muscle and joint pain, malaise, blurred vision, depression and dry mouth. Proton pump inhibitors decrease gastric acidity and may increase the risk of gastro-interstitial infections.

Cautions:

Proton pump inhibitors should be used with caution in patients with liver disease, in pregnancy and breast feeding: Before treatment the presence of gastric malignancy should be excluded.

No problem with Pantoprazole has been encountered in clinical use in elderly patients. No dosage adjustment of Pantoprazole is required in patients with renal impairment but prolongation of metabolism leading to a slight rise in peak plasma levels occurs in hepatic cirrhosis and it is recommended that the dosing is reduced to every other day.

Drug Interactions:

Pantoprazole does not react with the cytochrome P-450 system. No drug interaction has been reported in a large series of studies examining reactions with contraceptives, Diazepam, Diclofenac, Ethanol, Caffeine, Metoprolol, Theophylline, Digoxin, Phenytoin, Nifedipine and Warfarin. The absence of drug interactions may therefore be regarded as an advantage for Pantoprazole.

Storage Condition

Do not store above 25°C. Protect from light and keep in a dry place. Keep away from the reach of children.

Packaging:

Pantodac 20: Each box contains 6x10's tablets in blister pack.

Pantodac 40: Each box contains 3x10's tablets in blister pack.

Manufactured by



Ziska Pharmaceuticals Ltd.

Kaliakoir, Gazipur, Bangladesh